Bachem Holding AG
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BCHMF research report →
Companywww.bachem.com
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services.
- CEO
- Anne-Kathrin Stoller
- IPO
- 2011
- Employees
- 2,207
- HQ
- Bubendorf, CH
Price Chart
Valuation
- Market Cap
- $6.84B
- P/E
- 39.52
- P/S
- 8.46
- P/B
- 4.03
- EV/EBITDA
- 32.84
- Div Yield
- 1.15%
Profitability
- Gross Margin
- 28.74%
- Op Margin
- 21.62%
- Net Margin
- 21.41%
- ROE
- 10.56%
- ROIC
- 8.12%
Growth & Income
- Revenue
- $695.40M · 14.89%
- Net Income
- $148.86M · 23.80%
- EPS
- $1.98 · 23.75%
- Op Income
- $150.36M
- FCF YoY
- 65.13%
Performance & Tape
- 52W High
- $94.62
- 52W Low
- $60.51
- 50D MA
- $85.52
- 200D MA
- $69.38
- Beta
- 0.78
- Avg Volume
- 100
Get TickerSpark's AI analysis on BCHMF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BCHMF Coverage
We haven't published any research on BCHMF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BCHMF Report →